Transcranial Magnetic Stimulation (TMS)
Clinical Overview for Referring Providers
This page provides a structured clinical overview of transcranial magnetic stimulation (TMS) for clinicians seeking additional detail regarding mechanism, evidence base, safety, and referral considerations.
Overview
Transcranial magnetic stimulation (TMS) is an FDA-cleared, non-invasive neuromodulation treatment for major depressive disorder (MDD). It is most commonly considered for patients with treatment-resistant depression or those who have not achieved adequate response or tolerability with antidepressant medications.
Treatment is delivered in an outpatient setting. Patients remain awake during sessions and may resume normal activities immediately afterward.
Mechanism of Action
TMS delivers focused magnetic pulses to targeted cortical regions, most commonly the left dorsolateral prefrontal cortex (DLPFC). Repetitive stimulation modulates cortical excitability and influences interconnected neural networks implicated in mood regulation.
​
While the precise mechanisms remain under investigation, clinical and neurophysiological data support network-level modulation of fronto-limbic circuitry associated with depressive symptomatology.
Evidence Base
Randomized controlled trials have demonstrated statistically significant improvement in depressive symptom severity compared to sham stimulation in treatment-resistant populations.
​
Subsequent meta-analyses and real-world effectiveness studies support meaningful response and remission rates in appropriately selected patients. Outcomes are strongest in individuals meeting standard criteria for treatment-resistant depression.
​
TMS is recognized in major clinical guidelines as a treatment option for patients who have not responded adequately to antidepressant therapy.
When compared to outcomes from the STARD study, TMS efficacy in treatment-resistant populations is comparable or superior to next-step pharmacotherapy, with response rates of 24-37% in patients who had failed 1-2 antidepressant trials.
​
The Journal of Clinical Psychiatry. 2017. McClintock SM, Reti IM, Carpenter LL, et al.
Clinical Indications & Patient Selection
TMS may be appropriate for:
-
Major depressive disorder with inadequate response to ≥2 antidepressant trials
-
Intolerance to medication side effects
-
Persistent depressive symptoms despite psychotherapy
-
Preference to limit additional pharmacologic burden
​
Consider additional evaluation when:
-
History of seizure disorder
-
Presence of implanted metallic devices near the head
-
Bipolar spectrum illness (for diagnostic clarification prior to treatment)
Safety & Tolerability
TMS is generally well tolerated.
Most common side effects:
-
Scalp discomfort at stimulation site
-
Transient headache
Rare but serious risk:
-
Seizure (estimated <0.1% in appropriately screened patients)
There are no systemic medication side effects and no cognitive impairment associated with standard TMS protocols.
Insurance & Coverage
Most commercial insurers and Medicare provide coverage for TMS when medical necessity criteria are met, typically including documentation of prior antidepressant trials.
​
Coverage verification and authorization are coordinated prior to treatment initiation.
Program Structure at Mindcare
At Mindcare, TMS is delivered within a physician-directed clinical program that includes:
-
Comprehensive psychiatric evaluation
-
Diagnostic clarification when indicated
-
Structured treatment planning
-
Ongoing symptom monitoring
-
Communication with referring clinicians when consent is provided
​
Dr. Rossi completed fellowship training in TMS at Duke University and served as co-investigator for multiple neuromodulation clinical trials at Weill Cornell Medical College.